A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

September 23, 2022

Study Completion Date

September 23, 2022

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG

DRV/COBI FDC

DRV/COBI FDC tablet dispersed in water will be administered orally.

Trial Locations (6)

Rahima Moosa Mother and Child Hospital, University of Witwatersrand, Johannesburg

Hosp. Gral. Univ. Gregorio Maranon, Madrid

Hosp. Clinico San Carlos, Madrid

Hosp. Univ. La Paz, Madrid

Emory University, Atlanta

Global Clinical Trials PE, Pretoria

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY